You are here
P&T February 2014
Hospitals gain a year to meet stage 2 meaningful use rules.
FDA approvals, drug indications, and updates
Simeprevir (Olysio) for chronic hepatitis C infection; coagulation Factor XIII A-subunit (recombinant) (Tretten) for bleeding prevention in congenital Factor XIII A-subunit deficiency; and umeclidinium and vilanterol inhalation powder (Anoro Ellipta) for chronic obstructive pulmonary disease
Mipomersen (Kynamro) for homozygous familial hypercholesterolemia